Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas.

Area of Science:

• Hematology
• Oncology
• Molecular Pathology

Background:

• Diffuse large B cell lymphoma (DLBCL) exhibits significant clinical and genetic heterogeneity.
• A subset of DLBCL cases displays MYC locus translocations or a molecular profile akin to Burkitt lymphoma (mBL).
• Current diagnostic methods for these subtypes, relying on morphology, cytogenetics, or gene expression, are often unreliable or complex.

Purpose of the Study:

• To develop and validate an immunohistochemical (IHC) method for detecting increased MYC protein expression in DLBCL.
• To correlate IHC findings with MYC translocation status and gene expression profiles.
• To assess the clinical significance and prognostic value of MYC protein expression in DLBCL.

Main Methods:

• An immunohistochemical (IHC) assay was developed to quantify MYC protein expression in tumor cells.
• Seventy-seven DLBCL cases were analyzed using the IHC method.
• Gene set enrichment analysis (GSEA) was performed on transcriptional profiles to confirm MYC target gene upregulation.
• MYC translocation status and overall survival data were analyzed.

Main Results:

• The IHC assay identified 15 out of 77 DLBCL cases with high MYC protein expression (>50% nuclear staining).
• All cases with MYC translocations exhibited high MYC protein expression by IHC.
• Increased MYC protein expression correlated with upregulated MYC target genes, confirmed by GSEA.
• DLBCLs with high MYC protein expression demonstrated inferior overall survival when treated with R-CHOP.

Conclusions:

• The developed IHC method provides a reliable way to identify MYC-driven DLBCL.
• This IHC assay can distinguish biologically and clinically significant subsets of DLBCL.
• MYC-driven DLBCL represents a distinct subgroup with poor prognosis, particularly when treated with R-CHOP.